TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Overview
USA - NASDAQ:TNXP - US8902608392 - Common Stock
TNXP Key Statistics, Chart & Performance
The current stock price of TNXP is 18.62 USD. In the past month the price decreased by -28.38%. In the past year, price increased by 3.44%.
TNXP Latest News, Press Relases and Analysis
TNXP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.68 | 405.55B | ||
| AMGN | AMGEN INC | 13.7 | 160.87B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
| ARGX | ARGENX SE - ADR | 91.01 | 51.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.76B | ||
| INSM | INSMED INC | N/A | 35.04B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| NTRA | NATERA INC | N/A | 24.94B | ||
| BIIB | BIOGEN INC | 8.93 | 20.97B |
Related stock screener links
About TNXP
Company Profile
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 81 full-time employees. The company went IPO on 2010-03-29. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Company Info
TONIX PHARMACEUTICALS HOLDIN
26 Main Street, Suite 101
Chatham NEW JERSEY 07928 US
CEO: Seth Lederman
Employees: 81
Phone: 12129809155
TONIX PHARMACEUTICALS HOLDIN / TNXP FAQ
What is the stock price of TONIX PHARMACEUTICALS HOLDIN today?
The current stock price of TNXP is 18.62 USD. The price decreased by -1.01% in the last trading session.
What is the ticker symbol for TONIX PHARMACEUTICALS HOLDIN stock?
The exchange symbol of TONIX PHARMACEUTICALS HOLDIN is TNXP and it is listed on the Nasdaq exchange.
On which exchange is TNXP stock listed?
TNXP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TONIX PHARMACEUTICALS HOLDIN stock?
8 analysts have analysed TNXP and the average price target is 69.02 USD. This implies a price increase of 270.68% is expected in the next year compared to the current price of 18.62. Check the TONIX PHARMACEUTICALS HOLDIN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TONIX PHARMACEUTICALS HOLDIN worth?
TONIX PHARMACEUTICALS HOLDIN (TNXP) has a market capitalization of 163.30M USD. This makes TNXP a Micro Cap stock.
How many employees does TONIX PHARMACEUTICALS HOLDIN have?
TONIX PHARMACEUTICALS HOLDIN (TNXP) currently has 81 employees.
Is TONIX PHARMACEUTICALS HOLDIN (TNXP) expected to grow?
The Revenue of TONIX PHARMACEUTICALS HOLDIN (TNXP) is expected to decline by -10.16% in the next year. Check the estimates tab for more information on the TNXP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TNXP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TNXP, evaluating the profitability, health, valuation and growth aspects
- TONIX PHARMACEUTICALS HOLDIN (TNXP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TONIX PHARMACEUTICALS HOLDIN (TNXP) Sales and EPS estimates to see what analysts future expectations are.
- TONIX PHARMACEUTICALS HOLDIN (TNXP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TONIX PHARMACEUTICALS HOLDIN (TNXP) Insider and Institutional Ownership to learn about the owners and their transactions.
- TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Chart to make your own analysis
- TONIX PHARMACEUTICALS HOLDIN (TNXP) Latest news and press-releases to stay up to date.
Does TONIX PHARMACEUTICALS HOLDIN (TNXP) stock pay dividends?
TNXP does not pay a dividend.
When does TONIX PHARMACEUTICALS HOLDIN (TNXP) report earnings?
TONIX PHARMACEUTICALS HOLDIN (TNXP) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of TONIX PHARMACEUTICALS HOLDIN (TNXP)?
TONIX PHARMACEUTICALS HOLDIN (TNXP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-39.47).
What is the Short Interest ratio of TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?
The outstanding short interest for TONIX PHARMACEUTICALS HOLDIN (TNXP) is 15.21% of its float. Check the ownership tab for more information on the TNXP short interest.
TNXP Technical Analysis
TNXP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TNXP. TNXP has a great financial health rating, but its profitability evaluates not so good.
TNXP Financial Highlights
Over the last trailing twelve months TNXP reported a non-GAAP Earnings per Share(EPS) of -39.47. The EPS increased by 99.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.46% | ||
| ROE | -48.47% | ||
| Debt/Equity | 0 |
TNXP Forecast & Estimates
8 analysts have analysed TNXP and the average price target is 69.02 USD. This implies a price increase of 270.68% is expected in the next year compared to the current price of 18.62.
For the next year, analysts expect an EPS growth of 99.48% and a revenue growth -10.16% for TNXP